Beijing Xinhua Union Concord Pharmaceutical

Beijing Xinhua Union Concord Pharmaceutical is a China-based pharmaceutical company primarily focused on the dermatology and anti-infective sectors. Founded in 2001 as a joint venture between the Macrolink Group and the Institute of Medicinal Plant Development of the Chinese Academy of Medical Sciences, the company specializes in the research, development, and manufacturing of antifungal medications. Its portfolio includes several widely used topical treatments, most notably Luliconazole, for which it was the first manufacturer to receive approval in China. The company operates high-standard GMP manufacturing facilities in Beijing and leverages its strong academic ties to drive product innovation in the topical drug market. It is recognized as a key industrialization base for medicinal plant research in China.